Background: Clinical effectiveness of coronavirus disease 2019 (COVID‐19) vaccination in solid organ transplant recipients (SOTRs) is not well documented despite multiple studies demonstrating sub‐optimal immunogenicity.Methods: We reviewed medical records of eligible SOTRs at a single center to assess vaccination status and identify cases of symptomatic COVID‐19 from January 1 to August 12, 2021. We developed a Cox proportional hazards model using the date of vaccination and time since transplantation as a time‐varying covariate with age and gender as potential time‐invariant confounders. Survival curves were created using the parameters estimated from the Cox model. Results: Among 1904 SOTRs, 1362 were fully vaccinated (96% received mRNA vaccines) and 542 were either unvaccinated (n = 470) or partially vaccinated (n = 72). There were 115 cases of COVID‐19, of which 12 occurred in fully vaccinated individuals. Cox regression with the date of vaccination and time since transplantation as the time‐varying co‐variates showed that after baseline adjustment for age and sex, being fully vaccinated had a significantly lower hazard for COVID‐19, hazard ratio (HR) = 0.29 and 95% confidence interval ([CI] 0.09, 0.91).Conclusion: We found that 2‐dose mRNA COVID‐19 vaccination was protective of symptomatic COVID‐19 in vaccinated versus unvaccinated SOTRs.Tweet: COVID‐19 vaccination was associated with a significantly lower hazard for symptomatic COVID‐19 (HR 0.29; 95% CI 0.09, 0.91) among 1904 SOT recipients at a single center from January 1 to August 12, 2021.
Objectives: This study aims to determine the progression rate, risk factors and timeline for the progression from exposure to active tuberculosis (TB) in a high-risk population. Using a prospective cohort in the Republic of Moldova, we investigated pulmonary TB disease progression among close contacts of patients with TB in a low-burden country with high rates of drug-resistant TB. Methods: Close contacts of patients with newly diagnosed TB were recruited and monitored to evaluate for progression rates to active TB. Data collected included demographic information, medical and exposure history, and clinical samples. Follow-up clinical evaluations of close contacts were conducted at regular intervals over at least 24 months to monitor for progression to TB disease. Results: The overall incidence rate of TB disease among close contacts was 3.7%. Among the close contacts, 2.3% were identified as progressor cases, developing TB disease more than 30 days after index case treatment initiation. Thirteen (1.3%) were co-prevalent cases, diagnosed within 30 days of index case treatment initiation. Identified risk factors for progression included male sex, active tobacco use, prior TB infection, and frequent, prolonged exposure to index cases. Close contacts with daily exposure of more than eight hours had a significantly higher risk of disease progression (adjusted OR: 4.28, 95% CI: 1.79–10.23). Conclusion: The incidence of TB disease among close contacts was consistent with global findings, highlighting the need for enhanced diagnostic tools and targeted interventions to manage TB transmission and progression. These results underscore the importance of contact tracing and progression monitoring in low-burden, high drug-resistant TB settings. Future research should focus on developing a better understanding of factors contributing to the risk for and timeline of TB disease progression, and more precise methods, including biomarkers, to identify individuals at the highest risk for progression from TB exposure to active disease.
3 August 2023 in Journal of Microbiology, Immunology and Infection
To assess associations between disease severity in index TB patients and QuantiFERON-TB Gold Plus (QFT-Plus) results in contacts, and predictors for QFT-Plus conversion in contacts over 6-12 months. TB patients (n = 295) and the contacts (n = 1051) were enrolled during 2018-2021 with QFT-Plus performed at baseline and months 6 and 12. A strong CD8 response was defined as TB2 interferon gamma (IFN-γ) response minus TB1 >0.6 IU/ml and stringent conversion as change from QFT-plus negative to high-positive QFT-Plus (TB1 or TB2 IFN-γ responses >0.7 IU/ml). Contacts with index TB patients with sputum smear >1+ was associated with positive QFT-Plus compared to those without (p < 0.001). Contacts with index TB patients with bilateral lung disease were more likely to have strong CD8 responses than those without (p = 0.038). QFT-Plus stringent conversion occurred in 9.7% of contacts over 6-12 months. A TB1 IFN-γ response ≥0.03 IU/ml combined with a TB2 ≥0.06 IU/ml was predictive of a 19-fold increased risk for QFT-Plus stringent conversion in contacts (odd ratio 19.565 [8.484-45.116], p < 0.001). Bacterial burden and bilateral lung disease of index TB patients were associated with positive QFT-Plus and strong CD8 responses in contacts. TB1 and TB2 IFN-γ responses were synergistically predictive of stringent conversion in contacts.
While the goal of universal drug susceptibility testing has been a key component of the WHO End TB Strategy, in practice, this remains inaccessible to many. Rapid molecular tests for tuberculosis (TB) and antituberculosis drug resistance could significantly improve access to testing.
Guillain-Barré syndrome (GBS) is an ascending demyelinating polyneuropathy often associated with recent infection. Miller Fisher syndrome represents a variant with predominant facial and cranial nerve involvement, although Miller Fisher and Guillain-Barré overlap syndromes can occur. Guillain-Barré spectrum syndromes have been thought to be rare among solid organ transplant recipients. We describe an immunocompromised patient with a liver transplant who presented with ophthalmoplegia and bulbar deficits. His symptoms rapidly progressed to a state of descending paralysis involving the diaphragm; he then developed acute respiratory failure and eventually developed quadriparesis. Electromyography and a nerve conduction study demonstrated a severe sensorimotor axonal polyneuropathy consistent with Miller Fisher variant Guillain-Barré syndrome. Despite several negative nasopharyngeal swabs for COVID-19 polymerase chain reaction, a serology for SARS-CoV-2 IgG was positive. He was diagnosed with Miller Fisher-Guillain-Barré overlap syndrome with rapid recovery following treatment with plasma exchange. Although Guillain-Barré is a rare complication in solid organ transplant recipients, this case highlights the importance of rapid diagnosis and treatment of neurologic complications in transplant patients. Furthermore, it demonstrates a possible case of neurological complications from COVID-19 infection.
Background: Screening patients with asymptomatic active tuberculosis (TB) is crucial as they can transmit the disease. Identifying the risk factors for transmission is essential for targeted screening. Understanding how the infectiousness of asymptomatic patients with TB affects disease outcomes is crucial for developing strategies to control TB spread. Methods: We analyzed the national Korean TB cohort data to determine the factors associated with transmission risk and clinical outcomes in patients with asymptomatic pulmonary TB. The primary outcome was the factors associated with a risk factor for transmission, while the secondary outcome was mortality in asymptomatic patients with pulmonary TB stratified by transmission risk. Results: Among 20 455 patients with pulmonary TB, 7434 (36.4%) were asymptomatic, while 1520 (25.5%) had potential transmission risks, indicated by a positive sputum acid-fast bacillus smear test or cavitation on chest radiographs. The factors associated with a higher transmission risk included male sex (odds ratio [OR], 1.385; 95% CI, 1.172–1.636; P < .001), low body mass index (BMI; OR, 1.687; 95% CI, 1.420–2.004; P < .001), current smoking (OR, 1.443; 95% CI, 1.213–1.716; P < .001), diabetes (OR, 1.399; 95% CI, 1.201–1.629; P < .001), and autoimmune disease (OR, 2.233; 95% CI, 1.295–3.850; P = .004). The mortality rate was higher in patients with a risk factor for transmission risk than in those without (9.3 vs 7.1%; P = .008). Conclusions: Lean, smoking men with asymptomatic TB who have DM and/or autoimmune diseases have higher transmission and mortality risk. Asymptomatic populations with these risk factors warrant targeted screening.